Heterologous vaccination strategy for containing COVID-19 pandemic
Heterologous vaccination strategy for containing COVID-19 pandemic
Summary An unequitable vaccine allocation and continuously emerging SARS-CoV-2 variants pose challenges to contain the pandemic, which underscores the need for licensing more vaccine candidates, increasing manufacturing capacity and implementing better immunization strategy. Here, we report data from a proof-of-concept investigation in two healthy individuals who received two doses of inactivated whole-virus COVID-19 vaccines, followed by a single heterologous boost vaccination after 7 months with an mRNA vaccine candidate (LPP-Spike-mRNA) developed by Stemirna Therapeutics. Following the boost, Spike-specific antibody (Ab), memory B cell and T cell responses were significantly increased. These findings indicate that a heterologous immunization strategy combining inactivated and mRNA vaccines can generate robust vaccine responses and therefore provide a rational and effective vaccination regimen.
Ma Xiaopin、Zhao Fanfan、Shen Mingyun、Huang Lei、Jiang Erpeng、Li Qihan、Li Hangwen、Cui Pingfang、Zhang Yujian、Yao Weiguo、Li Yuhua、Wang Yue、Zhang Aihua、Liu JingJing、Liu Zhongmin、Huang Weijin、Lin Ang、He Jiaxin、Yu Bo、Tang Hongming、Wang Youchun
Stemirna Therapeutics Inc.Stemirna Therapeutics Inc.Stemirna Therapeutics Inc.Stemirna Therapeutics Inc.Shanghai East Hospital, Tongji UniversityInstitute of Medical Biology, Chinese Academy of Medical SciencesStemirna Therapeutics Inc.||National Institutes for Food and Drug Control (NIFDC)Institute of Medical Biology, Chinese Academy of Medical SciencesStemirna Therapeutics Inc.Stemirna Therapeutics Inc.National Institutes for Food and Drug Control (NIFDC)Shanghai East Hospital, Tongji UniversityStemirna Therapeutics Inc.National Institutes for Food and Drug Control (NIFDC)Shanghai East Hospital, Tongji UniversityNational Institutes for Food and Drug Control (NIFDC)Stemirna Therapeutics Inc.Stemirna Therapeutics Inc.Stemirna Therapeutics Inc.Shanghai East Hospital, Tongji UniversityNational Institutes for Food and Drug Control (NIFDC)
预防医学生物科学现状、生物科学发展生物科学研究方法、生物科学研究技术
Ma Xiaopin,Zhao Fanfan,Shen Mingyun,Huang Lei,Jiang Erpeng,Li Qihan,Li Hangwen,Cui Pingfang,Zhang Yujian,Yao Weiguo,Li Yuhua,Wang Yue,Zhang Aihua,Liu JingJing,Liu Zhongmin,Huang Weijin,Lin Ang,He Jiaxin,Yu Bo,Tang Hongming,Wang Youchun.Heterologous vaccination strategy for containing COVID-19 pandemic[EB/OL].(2025-03-28)[2025-05-17].https://www.medrxiv.org/content/10.1101/2021.05.17.21257134.点此复制
评论